Idalopirdine as a treatment for Alzheimer's disease

Research output: Contribution to journalArticle

Abstract

Introduction: Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Pharmacological treatment of AD involves acetylcholinesterase inhibitors (AChEIs) for mild-to-moderate AD and memantine for severe AD. These drugs provide mainly symptomatic short-term benefits without clearly counteracting the progression of the disease. Idalopirdine is an antagonist of the serotonin 6 (5-HT6) receptor, which is expressed in areas of the CNS involved with memory. Given that there is evidence suggesting that the blockade of 5-HT6 receptors induces acetylcholine release, it became reasonable to consider that 5-HT6 antagonism could also be a promising approach for restoring acetylcholine levels in a deteriorated cholinergic system. Areas covered: This review discusses the history leading to the discovery of idalopirdine, its pharmacokinetics and pharmacodynamics profile and safety issues, together with an overview of clinical trials carried out so far. A literature search was performed with PubMed using the keywords idalopirdine, AD and 5-HT6 antagonists. The article is also based on information derived from the ClinicalTrials.gov site for clinical trials with idalopirdine.Expert opinion: Idalopirdine is safe and well tolerated. It could be used as add-on therapy to potentiate the effect of available AChEIs in AD. Nevertheless, results from ongoing Phase III trials are needed to verify whether this drug has a significant clinical effect on cognition in association with AChEIs.

Original languageEnglish
Pages (from-to)981-987
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

    Fingerprint

Keywords

  • Alzheimer's disease
  • Antagonist
  • Clinical trial
  • Idalopirdine
  • LuAE58054
  • Receptor
  • Serotonin 6

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this